Theravance Biopharma Inc. (TBPH)
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review
The company is working with Lazard on a potential sale after its lead drug candidate disappointed in a late-stage study Theravance Biopharma shares collapsed 26% in morning trading on Tuesday after the company said it was exploring a potential sale following the failure of its most advanced drug candidate in a late-stage clinical trial. The company said ampreloxetine, which was being tested in patients with multiple system atrophy, a rare and progressive neurological condition that can cause a dangerous fall in blood pressure upon standing, failed to demonstrate a meaningful improvement in symptoms compared with patients receiving a placebo.
Is the Options Market Predicting a Spike in Theravance Biopharma Stock?
Investors need to pay close attention to TBPH stock based on the movements in the options market lately.
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 42.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?
Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?
The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Theravance Biopharma (TBPH) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
